Quantification of 111In-Pentetreotide Single Photon Emission Computed Tomography Images in Gastrointestinal Neuroendocrine Tumors and Possibility of Grade Prediction.
IF 2.7 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
{"title":"Quantification of <sup>111</sup>In-Pentetreotide Single Photon Emission Computed Tomography Images in Gastrointestinal Neuroendocrine Tumors and Possibility of Grade Prediction.","authors":"Makoto Ohba, Takeo Tanada, Yasushi Ishikawa, Satomi Teraoka, Kazukuni Kirii, Shin Ohara, Ayato Taketa, Taiyo Tanae, Yosuke Moriya, Koji Suzuki, Masafumi Kanoto","doi":"10.1007/s13139-025-00910-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Neuroendocrine tumors (NETs) can be classified into three grades based on the malignancy index identified via histological and pathological diagnosis, and <sup>111</sup>In-pentetreotide single photon emission computed tomography (SPECT) is effective for diagnosis. Therefore, this study aimed to distinguish between NET grade 1 (G1) and NET grade 2 (G2) based on the change in standardized uptake value (SUV) 4 and 24 h after injection in pancreatic and gastrointestinal NETs.</p><p><strong>Methods: </strong>Twenty-two patients underwent <sup>111</sup>In-pentetreotide SPECT and were definitively diagnosed with pancreatic or gastrointestinal NETs. The volume of interest were set in the tumor areas 4 and 24 h after injection, and SUV<sub>max</sub> and SUV<sub>mean</sub> were calculated. The ⊿tumor SUV (24 h-4 h) was calculated for each G1 and G2 by subtracting the SUV 4 h from SUV 24 h.</p><p><strong>Results: </strong>The ⊿tumor SUV<sub>max</sub> (24 h-4 h) was 19.35 ± 23.26 in G1 and - 13.30 ± 20.26 in G2, and the ⊿tumor SUV<sub>mean</sub> (24 h-4 h) was 7.64 ± 15.58 in G1 and - 8.89 ± 15.45 in G2. The ⊿tumor SUV<sub>max</sub> (24 h-4 h) and ⊿tumor SUV<sub>mean</sub> (24 h-4 h) were higher in G1 compared to G2 (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The ⊿tumor SUV (24 h-4 h) in patients with pancreatic/gastrointestinal NET on <sup>111</sup>In-pentetreotide SPECT images were higher in G1 compared to G2. The ⊿tumor SUV (24 h-4 h) for pancreatic and gastrointestinal NETs may predict the malignancy grade, as determined by histological and pathological diagnosis.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 3","pages":"194-200"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084186/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine and Molecular Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13139-025-00910-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Neuroendocrine tumors (NETs) can be classified into three grades based on the malignancy index identified via histological and pathological diagnosis, and 111In-pentetreotide single photon emission computed tomography (SPECT) is effective for diagnosis. Therefore, this study aimed to distinguish between NET grade 1 (G1) and NET grade 2 (G2) based on the change in standardized uptake value (SUV) 4 and 24 h after injection in pancreatic and gastrointestinal NETs.
Methods: Twenty-two patients underwent 111In-pentetreotide SPECT and were definitively diagnosed with pancreatic or gastrointestinal NETs. The volume of interest were set in the tumor areas 4 and 24 h after injection, and SUVmax and SUVmean were calculated. The ⊿tumor SUV (24 h-4 h) was calculated for each G1 and G2 by subtracting the SUV 4 h from SUV 24 h.
Results: The ⊿tumor SUVmax (24 h-4 h) was 19.35 ± 23.26 in G1 and - 13.30 ± 20.26 in G2, and the ⊿tumor SUVmean (24 h-4 h) was 7.64 ± 15.58 in G1 and - 8.89 ± 15.45 in G2. The ⊿tumor SUVmax (24 h-4 h) and ⊿tumor SUVmean (24 h-4 h) were higher in G1 compared to G2 (p < 0.05).
Conclusion: The ⊿tumor SUV (24 h-4 h) in patients with pancreatic/gastrointestinal NET on 111In-pentetreotide SPECT images were higher in G1 compared to G2. The ⊿tumor SUV (24 h-4 h) for pancreatic and gastrointestinal NETs may predict the malignancy grade, as determined by histological and pathological diagnosis.
期刊介绍：
Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging) is an official journal of the Korean Society of Nuclear Medicine, which bimonthly publishes papers on February, April, June, August, October, and December about nuclear medicine and related sciences such as radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. The journal specially welcomes works of artificial intelligence applied to nuclear medicine. The journal will also welcome original works relating to molecular imaging research such as the development of molecular imaging probes, reporter imaging assays, imaging cell trafficking, imaging endo(exo)genous gene expression, and imaging signal transduction. Nucl Med Mol Imaging publishes the following types of papers: original articles, reviews, case reports, editorials, interesting images, and letters to the editor.
The Korean Society of Nuclear Medicine (KSNM)
KSNM is a scientific and professional organization founded in 1961 and a member of the Korean Academy of Medical Sciences of the Korean Medical Association which was established by The Medical Services Law. The aims of KSNM are the promotion of nuclear medicine and cooperation of each member. The business of KSNM includes holding academic meetings and symposia, the publication of journals and books, planning and research of promoting science and health, and training and qualification of nuclear medicine specialists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
